Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics Inc (TSX:CRDL)

1.420 +0.060 (+4.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,052
Open 1.410
Bid (Size) 1.390 (10)
Ask (Size) 1.420 (20)
Prev. Close 1.360
Today's Range 1.360 - 1.420
52wk Range 1.090 - 2.170
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
(December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and 
Via PressReach
News headline image
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac... 
Via Newsfile

Performance

YTD
+4.4%
+4.4%
1 Month
+2.2%
+2.2%
3 Month
-5.3%
-5.3%
6 Month
-27.9%
-27.9%
1 Year
-28.6%
-28.6%

More News

Read More
News headline image
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Via PressReach
News headline image
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Via Newsfile
News headline image
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart
Via Newsfile
News headline image
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Via Newsfile
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN
Via AB Newswire
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
Via AB Newswire
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Via TheNewswire.com
News headline image
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Via News Direct
News headline image
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Via Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via TheNewswire.com
Topics ETFs
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
Via AB Newswire
News headline image
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
Via News Direct
News headline image
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Via Newsfile
News headline image
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Via Newsfile
News headline image
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Via Newsfile
News headline image
CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects ↗
Via Benzinga
News headline image
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
Via Newsfile
Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)
Via AB Newswire
Topics Stocks
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
Via AB Newswire
Topics Death
News headline image
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
Via Newsfile
News headline image
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
Via Newsfile
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
Via FinancialNewsMedia

Frequently Asked Questions

Is Cardiol Therapeutics Inc publicly traded?
Yes, Cardiol Therapeutics Inc is publicly traded.
What exchange does Cardiol Therapeutics Inc trade on?
Cardiol Therapeutics Inc trades on the Toronto Stock Exchange
What is the ticker symbol for Cardiol Therapeutics Inc?
The ticker symbol for Cardiol Therapeutics Inc is CRDL on the Toronto Stock Exchange
What is the current price of Cardiol Therapeutics Inc?
The current price of Cardiol Therapeutics Inc is 1.420
When was Cardiol Therapeutics Inc last traded?
The last trade of Cardiol Therapeutics Inc was at 01/05/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.